Proposed Amendment Would Provide Funds for FDA Oversight of CBD
Rep. Jerry McNerney (D-Calif.), in partnership with the Natural Products Association, has reportedly filed an amendment to the House Agriculture appropriations bill that would give the U.S. Food and Drug Administration (FDA) funding to undertake the process to identify a safe daily intake level of cannabidiol (CBD). “Since the passage of the 2018 Farm Act – which eliminated hemp from the definition of marijuana under the Controlled Substances Act – we’ve seen a significant increase in the production and sales of CBD products,” said McNerney in a June 18, 2019, press release. “With more and more CBD appearing on supermarket shelves across the country, it’s time for American consumers to have accurate information on CBD and for producers to be properly regulated to make the marketplace safe and reliable.”
FDA has also announced the extension of the comment period for the public hearing intended to “obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.” Comments will be accepted until July 2, 2019.
The Government of Canada has finalized regulations for the production and sale of edible cannabis and cannabis extracts, which will take effect October 17, 2019. License holders must provide 60 days’ notice to Health Canada of their intent to sell new products, so the announcement states that edible cannabis and cannabis-extract products will appear in “physical or online stores” “no earlier than mid-December 2019.”
